on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Advances on ONC010 Development Program
Onco-Innovations Limited has reported progress in the scale-up and development of key precursor components for its lead oncology program, ONC010. The Canadian company is focusing on optimizing the synthesis and manufacturing processes for the A83 and B4 precursors. These elements are essential for the nanoparticle formulation of ONC010, which targets solid tumors.
The ongoing work involves collaboration with Dalton Pharma Services to enhance process conditions, purification methods, and quality control measures. Recent efforts have improved purity and reproducibility across key production steps. Thomas O'Shaughnessy, CEO, highlights the significance of these advancements in fortifying ONC010's development path towards clinical trials.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news